Neumora Therapeutics, Inc. (NMRA)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Neumora Therapeutics: Downgrading After Navacaprant Development Setback
Neumora Therapeutics is downgraded from 'Strong Buy' to 'Hold' following KOASTAL-1's failure in the MDD primary endpoint. KOASTAL-2 and KOASTAL-3 studies for navacaprant in MDD have increased enrollment; topline data is expected in Q2 2026, but success remains uncertain. NMRA-511 showed a promising signal in phase 1b for Alzheimer's Disease agitation, with an enhanced effect in patients with elevated anxiety.
Neumora Therapeutics, Inc. (NMRA) Q4 2025 Earnings Call Transcript
Neumora Therapeutics, Inc. (NMRA) Q4 2025 Earnings Call Transcript
Neumora Therapeutics, Inc. (NMRA) Discusses Positive Phase 1b Results for NMRA-511 in Alzheimer's Disease Agitation Transcript
Neumora Therapeutics, Inc. (NMRA) Discusses Positive Phase 1b Results for NMRA-511 in Alzheimer's Disease Agitation Transcript
Neumora Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Point72 Asset Management LP Point72 Asset Management LP | 602,403 | $1.08M | $1.05M | -$30,120.21 | -2.79% |
 SkyOak Wealth SkyOak Wealth LLC | 150,000 | $97,573.33 | $261,000 | $163,426.67 | 167.49% |
| AA Andrew Alkon EntryPoint Capital, LLC | 110,875 | $198,466.14 | $192,922.5 | -$5,543.64 | -2.79% |
| AHI Addis & Hill Inc. Addis & Hill, Inc | 163,386 | $2.25M | $284,291.64 | -$1.96M | -87.34% |
| VT Vincent Tortorella Point72 (DIFC) Ltd | 51 | $37.42 | $88.74 | $51.32 | 137.16% |
Neumora Therapeutics, Inc. (NMRA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Neumora Therapeutics, Inc. ever had a stock split?
Neumora Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Daljit Singh Aurora CEO | NASDAQ (NGS) Exchange | 640979100 CUSIP |
| US Country | 110 Employees | - Last Dividend | - Last Split | 14 Sep 2023 IPO Date |
Overview
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical entity focused on innovating therapeutic solutions for a spectrum of brain-related conditions encompassing neuropsychiatric disorders and neurodegenerative diseases. Originally established as RBNC Therapeutics, Inc., the company rebranded to its current name in October 2021 and lays its foundational roots back to 2019. With its headquarters located in Watertown, Massachusetts, Neumora Therapeutics is at the forefront of advancing novel treatments aimed at addressing the complex challenges associated with brain diseases.
Products and Services
- Navacaprant (NMRA-140)
A pioneering once-daily oral kappa opioid receptor antagonist, currently under phase 3 clinical trials targeting the treatment of major depressive disorder. This novel compound exemplifies Neumora Therapeutics’ dedication to addressing mental health challenges with innovative therapeutic options.
- NMRA-511
Presently in phase 1 clinical trials, NMRA-511 is being developed for patients experiencing agitation associated with dementia, specifically Alzheimer's disease. This exploration emphasizes the company's commitment to alleviating symptoms of severe neuropsychiatric conditions associated with neurodegenerative disorders.
- NMRA-266
With its focus on schizophrenia and other neuropsychiatric disorders, NMRA-266 is in phase 1 clinical trial, signaling Neumora Therapeutics’ broader interest in addressing a range of mental health conditions through cutting-edge research and development.
- Preclinical Phase Products
The company’s pipeline also includes several products in preclinical phases: NMRA-NMDA for schizophrenia treatment highlights Neumora’s ongoing quest to unravel new therapies. NMRA-CK1d, targeting the treatment of amyotrophic lateral sclerosis (ALS), showcases the therapeutic exploration beyond conventional neuropsychiatric disorders. NMRA-NLRP3 is under development for certain neurodegenerative conditions, indicating a deep dive into the realm of neurodegenerative disease management. Lastly, NMRA-GCase for treating Parkinson’s disease exemplifies the company’s dedication to tackling neurodegenerative challenges with novel approaches.
